As of 2025-07-06, the Intrinsic Value of Protalix Biotherapeutics Inc (PLX) is 9.30 USD. This PLX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1.54 USD, the upside of Protalix Biotherapeutics Inc is 504.20%.
The range of the Intrinsic Value is 5.02 - 87.13 USD
Based on its market price of 1.54 USD and our intrinsic valuation, Protalix Biotherapeutics Inc (PLX) is undervalued by 504.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 5.02 - 87.13 | 9.30 | 504.2% |
| DCF (Growth 10y) | 7.79 - 131.03 | 14.24 | 824.9% |
| DCF (EBITDA 5y) | 5.27 - 5.80 | 5.52 | 258.7% |
| DCF (EBITDA 10y) | 7.59 - 9.14 | 8.32 | 440.4% |
| Fair Value | 0.25 - 0.25 | 0.25 | -84.06% |
| P/E | 1.54 - 1.54 | 1.54 | 0.1% |
| EV/EBITDA | 1.54 - 1.54 | 1.54 | 0.0% |
| EPV | 0.31 - 0.34 | 0.32 | -79.1% |
| DDM - Stable | 0.75 - 6.93 | 3.84 | 149.2% |
| DDM - Multi | 5.04 - 36.50 | 8.87 | 476.0% |
| Market Cap (mil) | 122.60 |
| Beta | 0.27 |
| Outstanding shares (mil) | 79.61 |
| Enterprise Value (mil) | 103.14 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.61% |
| Cost of Debt | 6.34% |
| WACC | 6.39% |